(NYSE:MRK), a global healthcare leader, finds itself at a crossroads as it navigates challenges in its China Gardasil business while capitalizing on opportunities in pulmonary arterial hypertension ...

The billionaire founder of Clayco issued a public statement along with a significant check for a political action committee ...

CARGO Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - CRGX ...

Jefferies analyst Michael Yee increased the price target for Akero Therapeutics stock, listed on (NASDAQ:AKRO), to $75 from ...

CARGO elects to discontinue FIRCE-1, a Phase 2 clinical study of firicabtagene autoleucel (firi-cel)1; Company believes results do not support a ...

As per the recent earnings update by FactSet dated 24th January 2025, the Q4 2024 earnings season for the S&P 500 has seen a ...

Akero Therapeutics (AKRO) reported 96-week data in its trial of advanced MASH patients, and there seem really significant ...

LATE-NC diagnostic criteria improve differentiation from Alzheimer's, addressing challenges in memory-loss syndromes and ...

Here we explore peptide inhibitors of Cdc20, a substrate-recognition subunit and activator of the E3 ubiquitin ligase the anaphase promoting complex/cyclosome (APC/C) that is essential in mitosis and ...

Akero Therapeutics’ impressive performance in both stock price and clinical trials has made it a stock to watch in 2025. With a promising treatment on the horizon and significant gains to show for it, ...

These two Fate series are a great way to pass the time until an official release date drops for the first season of ...

Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...